Novartis Pelacarsen Phase III Trial Fails to Reduce Cardiovascular Events

Novartis announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of red...

September 08, 2026 | Tuesday | News
Thryv Therapeutics Licenses Novel SGK1 Inhibitor Platform to Expand Into Neurodegenerative Diseases

Thryv Therapeutics Inc. ("Thryv"), a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, announced that it has entered into an ...

September 07, 2026 | Monday | News
Mabwell Reports Positive Phase Ib/IIa Results for Anti-ST2 Antibody 9MW1911 in COPD

Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the Phase Ib/IIa clinical results of its anti-S...

September 07, 2026 | Monday | News
AtomVie Opens $160 Million Radiopharmaceutical Manufacturing Facility in Ontario

AtomVie Global Radiopharma (AtomVie), a leading global Contract Development and Manufacturing Organization (CDMO) in the radiopharmaceutical industry, ce...

September 07, 2026 | Monday | News
Resonant Clinical Solutions Acquires Creapharm Bioservices to Expand European Biorepository Capabilities

Resonant Clinical Solutions, a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lifecycl...

September 07, 2026 | Monday | News
HCW Biologics Secures U.S. Patent Allowance for HCW9302 in Alopecia Areata

HCW Biologics Inc. (the “Company” or “HCW Biologics”), a U.S.-based clinical-stage biopharmaceutical company focused on developin...

September 04, 2026 | Friday | News
Inventiva Completes Final Patient Visits in Phase 3 NATiV3 Trial of Lanifibranor for MASH

Inventiva(“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral small m...

September 04, 2026 | Friday | News
Eisai and Biogen Win China Approval for Once-Weekly LEQEMBI Subcutaneous Autoinjector

Eisai Co., Ltd. and Biogen Inc. announced that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (su...

September 04, 2026 | Friday | News
Andelyn Biosciences to Scale Up Genprex’s AAV-Based Diabetes Gene Therapy Program

Andelyn Biosciences, a leading contract development and manufacturing organization, announced that Genprex, Inc. has selected Andelyn to support scale-up...

September 03, 2026 | Thursday | News
Telix Completes BiPASS Phase 3 Enrollment, Advances PSMA-PET Imaging for Earlier Prostate Cancer Diagnosis

Telix Pharmaceuticals Limited announced completion of patient enrollment in the Phase 3 BiPASS™ study of its commercial PSMA-PET imaging agent...

September 03, 2026 | Thursday | News
SciSparc Advances SCI-210 Clinical Trial for Autism Symptoms as Enrollment Reaches 26 Children

SciSparc Ltd. (“Company” or “SciSparc”), announced that NeuroThera Labs Inc.  ("NeuroThera"), a clinical-stage pharmaceuti...

September 02, 2026 | Wednesday | News
NexLife Expands Compounded GLP-1 Program With Four Protocols Under Flat-Rate Pricing Model

NexLife, a LegitScript-certified, physician-led telehealth platform, announced that its compounded GLP-1 program now spans four protocols under a single ...

September 02, 2026 | Wednesday | News
Arrowhead Pharmaceuticals’ Plozasiran Cuts Triglycerides by Up to 81% in Phase 3 SHASTA Trials

- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of p...

September 01, 2026 | Tuesday | News
Leios Therapeutics Grants CMS Exclusive China Rights to 10XB-101 for Focal Fat Reduction

10XB-101 is a Novel Potential Best-in-Class Injectable Drug Being Developed for Focal Fat Reduction and Body Contouring  Second Major Regional Lice...

September 01, 2026 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close